What happened with KRSA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Cyclerion Therapeutics, Inc., now renamed Korsana Biosciences, Inc., focuses on CYC-126, an experimental treatment for treatment-resistant depression and other neuropsychiatric conditions. It combines intravenous propofol and dexmedetomidine with a personalized delivery and monitoring system intended for hospitals. The approach aims to adjust sedation to specific brain-wave states; its therapeutic benefit is not established. The company has no product approved for commercial sale.
Most revenue comes from Akebia, which holds the worldwide license to praliciguat and pays Cyclerion for development milestones and related materials. Akebia handles the drug’s development, regulatory work and commercialization. Further milestone payments and potential royalties on sales depend on Akebia’s progress, and Akebia can terminate the agreement. Cyclerion has stopped developing its legacy soluble guanylate cyclase drug assets internally and seeks further licensing or other transactions to generate cash from them.
Advancing CYC-126 into Phase 2 trials requires additional capital. The company relies on financing and asset-related payments rather than sales of approved medicines to fund its work. SEC rules restrict how much equity it can sell through its shelf registration, and failure to secure funding could force it to delay or abandon CYC-126.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Korsana's new depression strategy hinges on funding and clinical validation of CYC-126, backed by MIT-licensed intellectual property and an option on Medsteer's delivery and monitoring technology.
Akebia Therapeutics, Inc. pays Korsana to license praliciguat and buy development materials, so its trial progress and eventual drug sales determine Korsana's milestone and royalty income. Starting the U.S. Phase 2 trial for FSGS triggered $1 million of Korsana's 2025 license revenue, paid in February 2026.
COMPASS Pathways Plc is developing clinic-delivered COMP360 psilocybin treatment for the same treatment-resistant depression patients Korsana aims to treat with hospital-based CYC-126. Watch COMP360's progress toward approval and, if approved, its reach into U.S. healthcare providers and clinic networks.
Axsome Therapeutics, Inc is a novel-therapy competitor to Korsana's CYC-126 depression program, but its marketed AUVELITY treats major depressive disorder rather than specifically treatment-resistant depression. AUVELITY sales are the relevant line to watch, rather than Axsome's combined revenue from depression, sleepiness and migraine medicines.
Helus Pharma Inc. is developing depression treatments that act on serotonin and could compete with Korsana's personalized CYC-126 for patients inadequately served by existing therapies.
Johnson & Johnson's marketed Spravato gives Korsana's proposed CYC-126 an established treatment-resistant depression therapy to compete against and be measured against. Its position in treating these patients is the relevant benchmark, rather than Johnson & Johnson's broader prescription-medicine business.
Korsana Biosciences, Inc. earningsThis company
Korsana Biosciences' report will show whether CYC-126 development and income from licensed assets can help the company keep operating.
Read cash and cash use alongside spending and progress on CYC-126, plus milestone and other license income from Akebia. Slower cash use with program progress or continuing license income would give Korsana more time to operate. Cash falling with stalled development and limited license payments would leave it more dependent on financing and at greater risk of curtailing or stopping operations.
